Medicina, Vol. 56 No. 4, 2020.
Pregledni rad
https://doi.org/10.21860/medflum2020_245218
Malignancies in renal transplant recipients
Tea Vukić
; Zavod za nefrologiju, arterijsku hipertenziju, dijalizu i transplantaciju, Klinički bolnički centar Zagreb, Medicinski fakultet Sveučilišta u Zagrebu, Zagreb, Hrvatska
Željko Kaštelan
; Klinika za urologiju, Klinički bolnički centar Zagreb, Medicinski fakultet Sveučilišta u Zagrebu, Zagreb, Hrvatska
Ivana Jurić
; Zavod za nefrologiju, arterijsku hipertenziju, dijalizu i transplantaciju, Klinički bolnički centar Zagreb, Medicinski fakultet Sveučilišta u Zagrebu, Zagreb, Hrvatska
Vesna Furić-Čunko
; Zavod za nefrologiju, arterijsku hipertenziju, dijalizu i transplantaciju, Klinički bolnički centar Zagreb, Medicinski fakultet Sveučilišta u Zagrebu, Zagreb, Hrvatska
Nikolina Bašić-Jukić
orcid.org/0000-0002-0221-2758
; Zavod za nefrologiju, arterijsku hipertenziju, dijalizu i transplantaciju, Klinički bolnički centar Zagreb, Medicinski fakultet Sveučilišta u Zagrebu, Zagreb, Hrvatska
Sažetak
End-stage renal disease requires the replacement of kidney function by different methods, the best of them being renal transplantation owing to significant survival advantage and better quality of life compared to the dialysis. In the beginnings of transplantation medicine, when transplantation was performed solely in young patients, and survival was relatively short due to acute rejections, malignant tumors were not a significant problem. In the era of modern immunosuppression, the leading cause of graft lost is death of a patient with functional graft. Malignant tumors are the third leading cause of death in patients following renal transplantation due to the increasing age of patients undergoing renal transplantation and longer cumulative influence of immunosuppression. Cardiovascular diseases and infections are the first and a second leading cause of death, respectively. According to Australian and New Zealand Dialysis and Transplant Registry, 10% of patients develop tumor 10 years after transplantation, 25% after 20 years, and after 30 years 40% of renal transplant recipients treated with immunosuppression develop malignancy. In a large population-based cohort study of 175 000 United States transplant recipients of solid organs, among those 10 656 developed some kind of a tumor. This is 2.1 times more often when compared to the general population. A significant increase of risk for 30 different primary tumors was reported, whereas a decreased incidence of breast cancer and prostate cancer was noted.
Ključne riječi
immunosuppression; malignant tumor; renal transplantation
Hrčak ID:
245218
URI
Datum izdavanja:
1.12.2020.
Posjeta: 1.169 *